Please fill out our easy to use form below. We will contact you today. Or, call us 24/7 TOLL FREE at 877-934-6274.
  • MM slash DD slash YYYY
  • By submitting this form you acknowledge that you have read the Terms of Use and accept the terms of this agreement.

Zinbryta Recall Announced

On March 2, 2018, Biogen and AbbVie, announced the withdrawal of Zinbryta (daclizumab) from the global market due to increasing safety concerns, including reports of encephalitis and meningoencephalitis cases in patients treated with Zinbryta. Zinbryta is used in the treatment of relapsing forms of multiple sclerosis.

FDA Zinbryta Recall Announcement

The U.S. Food and Drug Administration (FDA) reported that it will work with Zinbryta manufacturers “to help ensure a well-organized withdrawal from the market in the United States, and to ensure that health care professionals have the information they need to carefully transition their patients using Zinbryta to another treatment.” The FDA also indicated that “no new patients will start taking Zinbryta or participate in clinical studies.” Zinbryta will be available for patients as needed until April 30, 2018. Patients are cautioned to not stop taking their medication without talking to their doctor, and to contact their doctor immediately if they have any new and unexplained symptoms.

In addition to Zinbryta recall assistance, the FDA will conduct a review of reported inflammatory brain disorder cases in Zinbryta treated patients. Health care professionals and consumers are asked to report Zinbryta adverse reactions or quality problems to the FDA’s MedWatch reporting program.

The European Medicines Agency Announces Zinbryta Review And Zinbryta Recall

On February 3, 2018, the European Medicines Agency (EMA) announced that it was conducting an urgent review of Zinbryta following 7 cases of serious inflammatory brain disorders in Germany, including encephalitis and meningoencephalitis, and one case in Spain. The EMA also reported that Biogen would withdraw the medicine’s marketing authorizations, and stop ongoing Zinbryta clinical trials in the EU.

Obtain A Free Pharmaceutical Drug Lawsuit Evaluation

If you or a loved one has taken Zinbryta and has experienced a serious adverse event, please contact The Weinberg Law Firm for a free and non-obligatory legal consultation at 1-877-934-6274. You can also contact our firm online by submitting the easy-to-use “Free Legal Case Evaluation Form” found on this page.

Attorney Eric H. Weinberg has represented hundreds of individuals and thousands more class action claimants injured by the side effects of well known prescription drugs including Pradaxa, Vioxx, Ortho Evra, Baycol, and blood clotting products.

If you have a case-specific question, or a question regarding our legal services, please select
Contact Weinberg Law Firm. You may also call us 24/7 at our toll free number, 1(877) 934-6274.